Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer
- 19 November 2014
- journal article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 3 (2) , 415-419
Abstract
Malignant pleural effusion (MPE) is a common complication of lung cancer with devastating consequences. Since vascular endothelial growth factor (VEGF) has been implicated in MPE, we hypothesized that bevacizumab, an anti‑VEGF antibody, may be effective against MPE in patients with non‑small‑cell lung cancer (NSCLC). We analysed the records of 21 patients treated for NSCLC‑associated MPE between February, 2010 and August, 2013 who consequently underwent bevacizumab combination chemotherapy at the Institute of Biomedical Research and Innovation Hospital. The results were retrospectively analysed using case records and radiographic imaging records. Three patients exhibited complete response of the pleural effusion to bevacizumab treatment, 8 patients achieved a partial response (PR) and 6 patients showed no response. When efficacy was assessed by the response of the measurable primary or metastatic lesions to the treatment, 5 patients achieved a PR, 13 patients had stable disease and 3 patients exhibited progressive disease. The response rate (RR) of the pleural effusion to the antibody treatment was 71.4% and the overall rr of measurable lesions was 23.8%. The median time‑to‑response for pleural effusion was 132 days. In conclusion, this study demonstrated a high rR to bevacizumab combination therapy for the MPE associated with non‑squamous NSCLC. Therefore, bevacizumab therapy may be considered a therapeutic option for patients with non‑squamous NSCLC who develop MPE.Keywords
This publication has 27 references indexed in Scilit:
- Malignant Pleural EffusionsClinics in Chest Medicine, 2013
- Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in MicePLOS ONE, 2012
- Monoclonal anti‐vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusionRespirology, 2009
- Treatment options for malignant pleural effusionCurrent Opinion in Pulmonary Medicine, 2009
- The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant TumoursJournal of Thoracic Oncology, 2007
- Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitroAngiogenesis, 2004
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Targeting Vascular Endothelial Growth Factor Blockade: Ascites and Pleural Effusion FormationThe Oncologist, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Malignant effusions: Diagnostic evaluation and therapeutic strategyCurrent Problems in Cancer, 1981